SCHEDULE: Vanguard Amends Heron Therapeutics Stake

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 4.61% beneficial ownership stake in Heron Therapeutics Inc.

Summary

• The Vanguard Group reported beneficial ownership of 8,459,784 shares of Heron Therapeutics Inc. common stock.
• This ownership represents 4.61% of the class of securities.
• Vanguard holds sole dispositive power over 7,483,604 shares and shared dispositive power over 976,180 shares.
• Vanguard holds shared voting power over 917,424 shares and no sole voting power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of an institutional ownership stake, indicating a neutral sentiment as it primarily reports factual data without expressing explicit positive or negative views on the issuer's performance or future prospects.

Positives

• The continued significant institutional ownership by The Vanguard Group may signal long-term confidence in Heron Therapeutics Inc.

Future Outlook

NA

Industry Context

This filing reflects a routine disclosure by a major institutional asset manager, The Vanguard Group, regarding its passive investment stake in Heron Therapeutics Inc. Such filings are common and indicate ongoing portfolio management activities rather than specific strategic moves related to the issuer's industry position.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake can provide a degree of confidence or stability, indicating that a major fund manager sees value in holding the company's stock.

Key Dates

Keywords

Heron Therapeutics Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake